News
- Author:
- Nancy A. Melville
Publish date: June 6, 2023
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found no...
News
- Author:
- Nancy A. Melville
Publish date: June 6, 2023
“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement.”...
News
- Author:
- Nancy A. Melville
Publish date: June 5, 2023
At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.
News
- Author:
- Nancy A. Melville
Publish date: June 4, 2023
The immune checkpoint inhibitor nivolumab affords unprecedented improvement in “harmonizing” treatment for adult and pediatric Hodgkin lymphoma pat...
News
- Author:
- Nancy A. Melville
Publish date: June 1, 2023
Endocrinologists’ earnings still place them in the lowest five specialties in terms of pay, above infectious diseases, family medicine, pediatrics,...
News
- Author:
- Nancy A. Melville
Publish date: May 25, 2023
In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.
News
- Author:
- Nancy A. Melville
Publish date: May 25, 2023
Undergoing bariatric surgery was associated with a substantial and long-lasting reduction in the use of lipid-lowering and antidiabetic medications...
News
- Author:
- Nancy A. Melville
Publish date: May 17, 2023
The delays reported in time to definitive clinically meaningful deterioration “are particularly pertinent, given the anticipated continued improvem...
News
- Author:
- Nancy A. Melville
Publish date: May 1, 2023
CRC has a relatively high recurrence rate even after curative-intent therapies.
News
- Author:
- Nancy A. Melville
Publish date: April 17, 2023
“Clinicians should be aware that even minor weight loss of 5% or more in older adults without life-limiting illnesses can increase mortality risk.”...
News
- Author:
- Nancy A. Melville
Publish date: March 29, 2023
“This is an important study confirming that breast conservation is feasible and safe for women with multiple ipsilateral breast cancers, with excel...
News
- Author:
- Nancy A. Melville
Publish date: March 14, 2023
The American Academy of Sleep Medicine recommends CBT-I as first-line treatment for insomnia, with the key benefit being its exemplary safety profi...
News
- Author:
- Nancy A. Melville
Publish date: March 14, 2023
Overall, 48% of participants achieved a response, and 24% achieved remission of depressive symptoms following the first 4 weeks of twice-weekly tre...
News
- Author:
- Nancy A. Melville
Publish date: March 14, 2023
“These results are of great impact for clinicians managing older adults with treatment-resistant depression,” said Dr. Jennifer Gatchel.
News
- Author:
- Nancy A. Melville
Publish date: March 10, 2023
Brexpiprazole will become the first drug to be approved for agitation in AD, doctor speculates.
